ReAlta Life Sciences

Please note: The information displayed on this page might be outdated.
ReAlta Life Sciences: Developer of a new class of drugs designed to deploy a set of unique multi-modal therapeutic capabilities. The company's drugs have Complement inhibition (C1), anti-inflammatory, antioxidant and antimicrobial capabilities to provide game-changing therapy for multiple unmet or under-addressed medical needs, enabling healthcare professionals to address life-threatening medical needs through beneficial inhibition of the Complement System and Inflammatory Mechanisms.
Based in...
North America
Clinical Stage
Phase l or ll
Disease Space
Central Nervous System, Hematology, Infectious Disease, Respiratory
Innovation Research Park
4211 Monarch Way Suite 102
United States

Company Participants at Winter Private Company Showcase

Ulrich Thienel
ReAlta Life Sciences, CEO
Dr. Ulrich Thienel servedsas Chief Executive Officer & Board Member at ReAlta Life Sciences. He also served as Chief Medical Officer at Finch Therapeutics. He joined Finch with more than 20 years of experience successfully leading drug development programs for biotechnology and pharmaceutical companies, including RRD International, Takeda, Bristol-Myers Squibb, and Johnson & Johnson. Dr. Thienels development experience spans multiple therapeutic areas, including gastrointestinal, immunology, central nervous system, hematology, respiratory, and rare diseases. Throughout his career, Dr. Thienel has engaged in ten investigational new drug applications (INDs), two new drug applications (NDAs) and three biologics license applications (BLAs). He completed his M.D. and Ph.D. in Germany and a fellowship in rheumatology at Columbia University, New York.

Upcoming Company Event Participation